Neolaque (Amorolfine Hydrochloride)

Amorolfine, the active ingredient in Neolaque, blocks two key enzymes in the fungal ergosterol synthesis pathway—Δ14‑reductase and Δ7‑Δ8‑isomerase. By inhibiting these steps, the drug prevents formation of a functional cell membrane, leading to loss of membrane integrity and suppression of fungal growth.

The dosing regimen for Neolaque is determined by the prescribing healthcare professional. Typically, a thin layer is applied to the affected nail or skin once daily, but the exact frequency, amount, and duration depend on the severity of the infection and the clinician’s assessment.

Safety data for Amorolfine in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Neolaque to pregnant or nursing individuals. Consultation with a specialist is recommended.

To order Neolaque, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Neolaque (Amorolfine) differs from alternatives such as ciclopirox or terbinafine by targeting two distinct steps in ergosterol synthesis, which can result in a broader antifungal spectrum. Clinical experience suggests comparable efficacy for nail infections, while the formulation may offer better tolerability for some patients.

Neolaque should be stored at room temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and extreme temperatures. Keep the cap tightly closed when not in use to maintain stability.

Neolaque is applied topically to clean, dry skin or nail surfaces. A thin film is spread over the affected area, usually once daily, and allowed to dry. For nail infections, the medication may be applied to the nail plate and surrounding skin as directed by a clinician.

Serious adverse reactions, though rare, include severe allergic responses such as anaphylaxis, extensive contact dermatitis, angioedema, and persistent ulceration at the application site. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, or widespread rash.

Neolaque should be avoided in individuals with known hypersensitivity to Amorolfine or any component of the formulation. Caution is also advised for patients with extensive skin damage, open wounds, or those using conflicting topical medications without professional guidance.